Importantly, the frequency of TIGIT+CD28+ T cells that coexpressed DNAM-1 or granzyme B was significantly increased in patients with MM and these subsets thus likely represent the optimal targets for TIGIT inhibition (Figure 1F). The gene discussed is CD28; the disease is Miyoshi myopathy.